Download PDF
Klin Padiatr 2013; 225(03): 164-169
DOI: 10.1055/s-0033-1333749
Review
© Georg Thieme Verlag KG Stuttgart · New York

Adoptive T-cell Transfer for Refractory Viral Infections with Cytomegalovirus, Epstein-Barr Virus or Adenovirus after Allogeneic Stem Cell Transplantation

Adoptiver T-Zell-Transfer bei refraktären Virusinfektionen mit CMV, EBV oder ADV nach allogener Stammzelltransplantation
J. Feucht
1   Pediatric Hematology/Oncology, University Children’s Hospital Tübingen, Germany
,
L. Joachim
1   Pediatric Hematology/Oncology, University Children’s Hospital Tübingen, Germany
,
P. Lang
1   Pediatric Hematology/Oncology, University Children’s Hospital Tübingen, Germany
,
T. Feuchtinger
1   Pediatric Hematology/Oncology, University Children’s Hospital Tübingen, Germany
› Author Affiliations
Further Information

Publication History

Publication Date:
22 May 2013 (online)

Also available at
    Permissions and Reprints

Abstract

Viral infections after allogeneic stem cell transplantation (SCT) are an important cause of morbidity and mortality as SCT can expose patients to a transient state of combined immunodeficieny. Most viral infections after SCT are caused by the endogenous reactivation of persistent pathogens such as adenovirus (ADV), cytomegalovirus (CMV), and Epstein-Barr-virus (EBV). The control of these infections will ultimately depend on the restoration of adequate T-cell immunity.

Zusammenfassung

Nach allogener Blutstammzelltransplantation (SCT) stellen Virusinfektionen eine wichtige Ursache für lebensbedrohliche Zustände dar, die meist mit einem passageren kombinierten Immundefekt einhergehen. Mehrheitlich handelt es sich hierbei um die Reaktivierung persistierender Pathogene wie Adenoviren (ADV), Cytomegalie-Virus (CMV) oder Epstein­-Barr-Virus (EBV). Die Kontrolle dieser Infektionen hängt wesentlich von der adäquaten Erholung der T-Zell-Funktion ab.

Key words

virus infection - allogeneic stem cell ­transplantation - T-cell transfer

Schlüsselwörter

Virusinfektion - allogene Stammzell­transplantation - T-Zell-Transfer
 

  • References

  • 1 Boeckh M, Nichols WG. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood 2004; 103: 2003-2008
    CrossrefPubMedGoogle Scholar
  • 2 Einsele H, Hebart H, Kauffmann-Schneider C et al. Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection. Bone Marrow Transplant 2000; 25: 757-763
    CrossrefPubMedGoogle Scholar
  • 3 Schuster FR, Simon A, Laws HJ et al. Viral infections in pediatric cancer patients. Klin Padiatr 2005; 217 (Suppl. 01) S67-S84
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Mohty M, Jacot W, Faucher C et al. Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK 2003; 17: 2168-2177
    CrossrefPubMedGoogle Scholar
  • 5 Kapp M, Tan SM, Einsele H et al. Adoptive immunotherapy of HCMV infection. Cytotherapy 2007; 9: 699-711
    CrossrefPubMedGoogle Scholar
  • 6 Koehl U, Dirkwinkel E, Koenig M et al. Reconstitution of cytomegalovirus specific T cells after pediatric allogeneic stem cell transplantation: results from a pilot study using a multi-allele CMV tetramer group. Klin Padiatr 2008; 220: 348-352
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Flomenberg P, Babbitt J, Drobyski WR et al. Increasing incidence of adenovirus disease in bone marrow transplant recipients. J Infect Dis 1994; 169: 775-781
    CrossrefPubMedGoogle Scholar
  • 8 Shields AF, Hackman RC, Fife KH et al. Adenovirus infections in patients undergoing bone-marrow transplantation. N Engl J Med 1985; 312: 529-533
    CrossrefPubMedGoogle Scholar
  • 9 Feuchtinger T, Lang P, Handgretinger R. Adenovirus infection after allogeneic stem cell transplantation. Leuk Lymphoma 2007; 48: 244-255
    CrossrefPubMedGoogle Scholar
  • 10 La Rosa AM, Champlin RE, Mirza N et al. Adenovirus infections in adult recipients of blood and marrow transplants. Clin Infect Dis 2001; 32: 871-876
    CrossrefPubMedGoogle Scholar
  • 11 Feuchtinger T, Richard C, Pfeiffer M et al. Adenoviral infections after transplantation of positive selected stem cells from haploidentical donors in children: an update. Klin Padiatr 2005; 217: 339-344
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Echavarria M, Forman M, van Tol MJ et al. Prediction of severe disseminated adenovirus infection by serum PCR. Lancet 2001; 358: 384-385
    CrossrefPubMedGoogle Scholar
  • 13 Lion T, Baumgartinger R, Watzinger F et al. Molecular monitoring of adenovirus in peripheral blood after allogeneic bone marrow transplantation permits early diagnosis of disseminated disease. Blood 2003; 102: 1114-1120
    CrossrefPubMedGoogle Scholar
  • 14 Ocheni S, Kroeger N, Zabelina T et al. EBV reactivation and post transplant lymphoproliferative disorders following allogeneic SCT. Bone Marrow Transplant 2008; 42: 181-186
    CrossrefPubMedGoogle Scholar
  • 15 Handgretinger R, Lang P, Schumm M et al. Immunological aspects of haploidentical stem cell transplantation in children. Ann N Y Acad Sci 2001; 938: 340-357; discussion 57–58
    PubMedGoogle Scholar
  • 16 Chiusolo P, Metafuni E, Cattani P et al. Prospective Evaluation of Epstein-Barr Virus Reactivation After Stem Cell Transplantation: Association with Monoclonal Gammopathy. J Clin Immunol 2010; 30: 894-902
    CrossrefPubMedGoogle Scholar
  • 17 Tran H, Nourse J, Hall S et al. Immunodeficiency-associated lymphomas. Blood Rev 2008; 22: 261-281
    CrossrefPubMedGoogle Scholar
  • 18 Buyck HC, Ball S, Junagade P et al. Prior immunosuppressive therapy with antithymocyte globulin increases the risk of EBV-related lymphoproliferative disorder following allo-SCT for acquired aplastic anaemia. Bone Marrow Transplant 2009; 43: 813-816
    CrossrefPubMedGoogle Scholar
  • 19 Bahceci E, Epperson D, Douek DC et al. Early reconstitution of the T-cell repertoire after non-myeloablative peripheral blood stem cell transplantation is from post-thymic T-cell expansion and is unaffected by graft-versus-host disease or mixed chimaerism. British journal of haematology 2003; 122: 934-943
    CrossrefPubMedGoogle Scholar
  • 20 Lewin SR, Heller G, Zhang L et al. Direct evidence for new T-cell generation by patients after either T-cell-depleted or unmodified allogeneic hematopoietic stem cell transplantations. Blood 2002; 100: 2235-2242
    PubMedGoogle Scholar
  • 21 Wagner HJ, Cheng YC, Huls MH et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood 2004; 103: 3979-3981
    CrossrefPubMedGoogle Scholar
  • 22 Meij P, van Esser JW, Niesters HG et al. Impaired recovery of Epstein-Barr virus (EBV)-specific CD8+T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease. Blood 2003; 101: 4290-4297
    CrossrefPubMedGoogle Scholar
  • 23 van Esser JW, van der Holt B, Meijer E et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood 2001; 98: 972-978
    CrossrefPubMedGoogle Scholar
  • 24 Heslop HE. How I treat EBV lymphoproliferation. Blood 2009; 114: 4002-4008
    CrossrefPubMedGoogle Scholar
  • 25 Heslop HE, Li C, Krance RA et al. Epstein-Barr infection after bone marrow transplantation. Blood 1994; 83: 1706-1708
    PubMedGoogle Scholar
  • 26 Leen AM, Tripic T, Rooney CM. Challenges of T cell therapies for virus-associated diseases after hematopoietic stem cell transplantation. Expert Opin Biol Ther 2010; 10: 337-351
    CrossrefPubMedGoogle Scholar
  • 27 Walter EA, Greenberg PD, Gilbert MJ et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995; 333: 1038-1044
    CrossrefPubMedGoogle Scholar
  • 28 Einsele H, Roosnek E, Rufer N et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002; 99: 3916-3922
    CrossrefPubMedGoogle Scholar
  • 29 Peggs KS, Verfuerth S, Pizzey A et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 2003; 362: 1375-1377
    CrossrefPubMedGoogle Scholar
  • 30 Micklethwaite KP, Clancy L, Sandher U et al. Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation. Blood 2008; 112: 3974-3981
    CrossrefPubMedGoogle Scholar
  • 31 Rooney CM, Smith CA, Ng CY et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995; 345: 9-13
    CrossrefPubMedGoogle Scholar
  • 32 Gattinoni L, Klebanoff CA, Palmer DC et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest 2005; 115: 1616-1626
    CrossrefPubMedGoogle Scholar
  • 33 Feuchtinger T, Opherk K, Bethge WA et al. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood 2010; 116: 4360-4367
    CrossrefPubMedGoogle Scholar
  • 34 Feuchtinger T, Matthes-Martin S, Richard C et al. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. British journal of haematology 2006; 134: 64-76
    CrossrefPubMedGoogle Scholar
  • 35 Cobbold M, Khan N, Pourgheysari B et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med 2005; 202: 379-386
    CrossrefPubMedGoogle Scholar
  • 36 Schmitt A, Tonn T, Busch DH et al. Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation. Transfusion 2011; 51: 591-599
    CrossrefPubMedGoogle Scholar
  • 37 Uhlin M, Gertow J, Uzunel M et al. Rapid salvage treatment with virus-specific T cells for therapy-resistant disease. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 2012; 55: 1064-1073
    CrossrefPubMedGoogle Scholar
  • 38 Rooney CM, Smith CA, Ng CY et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998; 92: 1549-1555
    PubMedGoogle Scholar
  • 39 Einsele H, Rauser G, Grigoleit U et al. Induction of CMV-specific T-cell lines using Ag-presenting cells pulsed with CMV protein or peptide. Cytotherapy 2002; 4: 49-54
    CrossrefPubMedGoogle Scholar
  • 40 Leen AM, Myers GD, Sili U et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 2006; 12: 1160-1166
    CrossrefPubMedGoogle Scholar
  • 41 Riddell SR, Watanabe KS, Goodrich JM et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 1992; 257: 238-241
    CrossrefPubMedGoogle Scholar
  • 42 Papadopoulos EB, Ladanyi M, Emanuel D et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994; 330: 1185-1191
    CrossrefPubMedGoogle Scholar
  • 43 Heslop HE, Slobod KS, Pule MA et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2010; 115: 925-935
    CrossrefPubMedGoogle Scholar
  • 44 Haque T, Wilkie GM, Taylor C et al. Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet 2002; 360: 436-442
    CrossrefPubMedGoogle Scholar
  • 45 Haque T, Wilkie GM, Jones MM et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 2007; 110: 1123-1131
    CrossrefPubMedGoogle Scholar
  • 46 Icheva V, Kayser S, Wolff D et al. Adoptive Transfer of Epstein-Barr Virus (EBV) Nuclear Antigen 1-Specific T Cells As Treatment for EBV Reactivation and Lymphoproliferative Disorders After Allogeneic Stem-Cell Transplantation. J Clin Oncol 2013; 31: 39-48
    CrossrefPubMedGoogle Scholar
  • 47 Feuchtinger T, Richard C, Pfeiffer M et al. Adenoviral infections after transplantation of positive selected stem cells from haploidentical donors in children: An update. Klinische Padiatr 2005; 217: 339-344
    PubMedGoogle Scholar
  • 48 Leen AM, Christin A, Myers GD et al. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood 2009; 114: 4283-4292
    CrossrefPubMedGoogle Scholar